← Eichor
Condition: Stomach Cancer Stage Iv Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Stomach Cancer Stage Iv

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Pa
Phase 2 · 2 location(s) · Shanghai Zhongshan Hospital · NCT06468280Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
NA · 2 location(s) · University of California, San Francisco · NCT04221893DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinom
Phase 2/Phase 3 · 12 location(s) · RemeGen Co., Ltd. · NCT06221748Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Phase 2 · 2 location(s) · Massachusetts General Hospital · NCT07070466M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1
Phase 3 · 1 location(s) · FutureGen Biopharmaceutical (Beijing) Co., Ltd · NCT06177041Intravital Microscopy in Human Solid Tumors
NA · 1 location(s) · Mayo Clinic · NCT03823144Identification of Therapeutic Targets in Metastatic Gastric Cancer
Phase N/A · 1 location(s) · Chinese University of Hong Kong · NCT07551440BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer
Phase 1 · 1 location(s) · Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · NCT06773312Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
Phase 1/Phase 2 · 1 location(s) · National Health Research Institutes, Taiwan · NCT05927857First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Phase 2 · 20 location(s) · Qilu Hospital of Shandong University · NCT06730373First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
Phase 2 · 37 location(s) · GERCOR - Multidisciplinary Oncology Cooperative Group · NCT06253611Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Ca
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03161522Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410Liver Embolization Approaches for Tumor Management
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT05714124Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenoca
Phase 2 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07102901A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmaco
Phase 1 · 2 location(s) · Vall d'Hebron Institute of Oncology · NCT07593820Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer
Phase 1/Phase 2 · 1 location(s) · Yonsei University · NCT04592211mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · 794 location(s) · Alliance for Clinical Trials in Oncology · NCT05677490Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Phase 2 · 6 location(s) · I-Mab Biopharma US Limited · NCT07432295PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
Phase 2 · 1 location(s) · Peking University Third Hospital · NCT06792162A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
Phase 1/Phase 2 · 1 location(s) · Cancer Hospital Chinese Academy of Medical Science, Shenzhen · NCT06776770Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer
NA · 1 location(s) · University Medical Center Ho Chi Minh City (UMC) · NCT06768463A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
Phase N/A · 1 location(s) · Akeso · NCT07547787Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric
Phase 2 · 1 location(s) · Beijing Friendship Hospital · NCT07315854Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastro
Phase 2/Phase 3 · 69 location(s) · Pfizer · NCT07392892Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
NA · 1 location(s) · Cedars-Sinai Medical Center · NCT04907643Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
Phase 4 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT05183126A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 · 19 location(s) · NiKang Therapeutics, Inc. · NCT06586957Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gast
Phase 1 · 3 location(s) · City of Hope Medical Center · NCT04329494
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.